Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults
Aesthetic Surgery Journal · 18.05.2026 · 46 (6) · 672-679
DOI: 10.1093/asj/sjag042 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 14.02.2026. Verfasst von Yan Wu und 20 weiteren Autor:innen. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Neuromuscular Agents, Cosmetic Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing Claruvis.
Abstract (Originalsprache)
Background
Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.
Objectives
To evaluate the efficacy, safety, and immunogenicity of YY001, a recombinant botulinum toxin type A (Chongqing Claruvis Pharmaceutical Co., Ltd., Chongqing, China), in the treatment of moderate-to-severe glabellar lines.
Methods
In this multicenter, randomized, double-blind, vehicle- and active-controlled Phase III trial, 529 adults aged 18-65 with moderate to severe glabellar lines were randomized 4:2:1 to receive a single 20 U injection of YY001, Botox®(Allergan Pharmaceuticals Ireland, Westport, Ireland), or vehicle. The primary endpoint was composite response rate (CRR) at Week 4, defined as a ≥2-grade improvement of glabellar line severity assessed by both investigator and participant. Secondary endpoints included onset time, duration, satisfaction, and safety.
Results
YY001 achieved a CRR of 86.7% at Week 4, significantly outperforming Botox® (66.7%, P < .0001) and vehicle (1.3%, P < .0001). It showed faster onset, longer median duration (97 days), and high participant satisfaction. Adverse events were mild and comparable across groups. Only one case of anti-drug antibody was observed; no neutralizing antibodies were detected. A 12-week follow-up and ethnically homogenous population may limit generalizability.
Conclusions
YY001 demonstrated strong efficacy and a favorable safety profile than Botox®. Longer-term and multicenter studies are needed to assess durability, immunogenicity, and applicability across broader populations. Level of Evidence: 1 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Xiao Long
Förderung
- Chongqing Claruvis
Zitieren
APA
Wu, Y., Long, X., Yu, N., Chen, J., Lu, J., Tan, L., Lai, W., Li, L., Wu, S., Wu, L., Sun, J., Bi, H., Geng, S., Wang, H., Luo, S., Hu, Z., Yang, J., Wang, B., Yang, W., …, & Sun, X. (2026). Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults. Aesthetic Surgery Journal, 46(6), 672-679. https://doi.org/10.1093/asj/sjag042
Vancouver
Wu Y, Long X, Yu N, Chen J, Lu J, Tan L, et al. Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults. Aesthetic Surgery Journal. 2026;46(6):672-679. doi:10.1093/asj/sjag042
BibTeX
@article{Wu2026,
author = {Wu, Yan and Long, Xiao and Yu, Nanze and Chen, Jin and Lu, Jianyun and Tan, Lina and Lai, Wei and Li, Li and Wu, Sufan and Wu, Liming and Sun, Jiaming and Bi, Hongsen and Geng, Songmei and Wang, Huiping and Luo, Shengkang and Hu, Zhiqi and Yang, Jianmin and Wang, Baoxi and Yang, Wu and Sun, Xiaoli and Sun, Xiaoyun},
title = {Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults},
journal = {Aesthetic Surgery Journal},
year = {2026},
volume = {46},
number = {6},
pages = {672--679},
doi = {10.1093/asj/sjag042}
}
EUVIMED